Intralytix, Inc. is a biotechnology company focused on the discovery, production and marketing of bacteriophage-based products to control bacterial pathogens in environmental, food processing, and medical settings.

Bacteriophages (bacteria-eater: from the Greek phago meaning "to eat" or "to develop at the expense of") are the most abundant microorganisms on earth. They are the natural enemies of bacteria. Lytic bacteriophages can very effectively kill their targeted specific bacteria without affecting anything else, ensuring an unprecedented level of safety for an antimicrobial.

In The News

Intralytix awarded patent by USPTO for novel Shigella bacteriophages and their uses

Intralytix, Inc. announced today that it has been issued a patent by the U.S. Patent & Trademark Office (USPTO) covering its Shigella bacteriophages and their various applications. The patent broadly relates to several bacteriophages with strong lytic potency against Shigella spp., and their various formulations. The patent also covers specific uses of these formulations, such as improving food safety and human health, including maintaining healthy gut microflora by modulating a mammal's microbiome and by reducing colonization by Shigella or levels of Shigella in the gut.

Leading Bacteriophage Company Expands Clinical Pipeline, Poised for Growth in Maryland

Intralytix, the largest food safety phage company in the world, sits on the precipice of substantial growth and success. 23 years of building unrivaled bacteriophage expertise, developing and securing 15 issued patents, and being one of two phage companies in the world with sales revenue have put this Columbia, Maryland-based company in a position to harness several positive macro-market forces to fuel its expansion.

Intralytix enters into CRADA with the U.S. Army Combat Capabilities Development Command Soldier Center

Intralytix, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Combat Capabilities Development Command Soldier Center (CCDC SC) in Natick, Massachusetts. The CRADA will focus on developing a dehydration process for bacteriophage cocktails, for use as a non-chemical and environmentally friendly food safety intervention and mitigation strategy for bacterial pathogens in fresh military procured food items.

Intralytix Receives Multimillion-Dollar Clinical Trial Award From NIAID to Manage Shigella Infections in Humans

Intralytix, Inc. announced today that it has received a multimillion-dollar grant (AI 148054) from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), for the clinical development of its bacteriophage therapy preparation for managing infections caused by the bacterial pathogen Shigella.

See more...


Food Safety

Environmental Sanitation

Veterinary Applications

Human Therapeutics